May 3, 2019
ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators…
Pharmaceuticals, Biotechnology and Life Sciences
Author: BusinessWire
May 3, 2019
New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
– New data published in NEJM confirm sustained three-year treatment effect – – Data will also be presented in Emerging…
May 3, 2019
Contextual Genomics Names Sue Paish as Chair of the Board of Directors
VANCOUVER, British Columbia–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/cancergenomics?src=hash" target="_blank"gt;#cancergenomicslt;/agt;–Contextual Genomics announced today that Sue Paish will become the new Chair of the Company’s…
May 3, 2019
Utah Medical Innovations Pathways (MIP) Graduates Celebrated at State Capitol Ceremony
High school seniors from five Utah school districts were awarded the Medical Innovations Certificate during a graduation ceremony at the…
May 3, 2019
Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class…
May 2, 2019
Zymeworks Reports 2019 First Quarter Financial Results
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the…
May 2, 2019
Axial Biotherapeutics develops AB-2004 as potential treatment for gastrointestinal dysfunction
– Preclinical results support development of AB-2004 as potential treatment for gastrointestinal dysfunction and associated behavioral symptoms of Autism Spectrum…
May 2, 2019
FSD Pharma delays 2018 Year-End Filings, working with new auditing firm in advance of listing on the NYSE
FSD Pharma delays 2018 Year-End Filings, working with new auditing firm in advance of listing on the NYSE
May 2, 2019
Vivera Pharmaceuticals names new Chief Medical Officer
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CBD?src=hash” target=”_blank”gt;#CBDlt;/agt;–Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announced the appointment…
May 2, 2019
bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress
– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years…